How emerging investment models are rewiring biotech funding structures for efforts in rare disease.
Rob Freishtat, MD
Advertisement
Rob Freishtat, MD, strategic Advisor and life science consultant.
Articles by Rob Freishtat, MD
Advertisement
Latest Updated Articles
The New Capital of Care in Rare DiseaseJune 10th 2026
Advertisement
Advertisement
Trending on PharmExec
1
U.S. House Committee Investigating Drugmakers Involved in China Drug Trials: Report
2
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
3
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
4
FDA Announces Seven Participants to PreCheck Pilot Program
5